Major depressive disorder is a leading cause of disability worldwide. Because conventional
therapies are ineffective in many patients, novel strategies are needed to overcome …

Disturbances in the glutamatergic system have been increasingly documented in several
neuropsychiatric disorders, including autism spectrum disorder (ASD). Glutamate-centered …

Serotonin reuptake inhibitors and benzodiazepines are evidence-based pharmacological
treatments for Anxiety Disorders targeting serotonin and GABAergic systems, respectively …

Patients with cancer are at greater risk of developing depression in comparison to the
general population and this is associated with serious adverse effects, such as poorer …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease caused by
the death of motor neurons. Riluzole is a benzothiazole derivative that blocks glutamatergic …

The development of current neuroleptics was largely aiming to decrease excessive
dopaminergic signaling in the striatum. However, the notion that abnormal dopamine …

In the last decade there has been a revolution in terms of genetic findings in
neurodevelopmental disorders (NDDs), with many discoveries critical for understanding …

Treatment-resistant depression (TRD) is a term used to describe a particular type of major
depressive disorder (MDD). There is no consensus about what defines TRD, with various …

Methods This systematic review aims to investigate the effects of ketamine in OCD, following
the Preferred Reporting Items for Systematic Review and Meta-analyses Protocols (PRISMA …

Importance Psychiatric disorders display high levels of comorbidity and genetic overlap,
necessitating multivariate approaches for parsing convergent and divergent psychiatric risk …